Actively Recruiting
Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2025-05-09
36
Participants Needed
3
Research Sites
165 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Fiber is the main source of energy for colonic bacteria and its consumption favorably modifies the composition of the microbiota in only a few days. Their fermentation in the colon releases short-chain fatty acids (SCFAs). Clostridiales contain many strains producing SCFAs. These SCFAs can restore the intestinal barrier and promote certain anti-inflammatory cells, including regulatory T cells (Tregs), which are essential to the mechanisms in tolerance of the self. Fibers could therefore correct the intestinal abnormalities present in patients with axial spondyloarthritis (AxSpA) and aggravated by anti-IL-17 drugs and thus improve the therapeutic response to these treatments. The hypothesis is that dietary fiber will correct the dysbiosis in AxSpA patients and increase the release of SCFAs, which favorably modulate the immune response and improve AxSpA.
CONDITIONS
Official Title
Optimizing Anti-IL17 Antibody Therapy by Associating Fiber Supplementation to Correct Treatment-aggravated Gut Dysbiosis in Axial Spondyloarthritis - RESPOND-IL17
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with spondyloarthritis meeting the ASAS criteria
- Patients planned for anti-IL-17 biomedication by their rheumatologist
- Aged between 18 and 90 years
- Affiliated with the French social security system or beneficiaries
- Women of childbearing age must use effective contraception or have no desire to become pregnant during the study period
You will not qualify if you...
- No written informed consent provided
- Participation in other therapeutic research with ongoing exclusion period
- Under court protection, guardianship, or curatorship
- Unable to give consent
- Pregnant or breastfeeding
- Digestive disorders without exclusion of chronic inflammatory bowel disease
- Fructose intolerance or glucose/galactose malabsorption
- Known intolerance to inulin or maltodextrin
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Nîmes University Hospital
Nîmes, Gard, France, 30029
Actively Recruiting
2
Montpellier University Hospital
Montpellier, Hérault, France, 34000
Actively Recruiting
3
Tours Regional University Hospital (Bretonneau)
Tours, Indre-et-Loire, France, 37032
Actively Recruiting
Research Team
C
Cédric LUKAS, Professor
CONTACT
A
Anissa MEGZARI
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here